



CASE 4-21233/APCT

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL820010508US
Express Mail Label Number

August 20, 2002
Date of Deposit

TECH CENTER 1600/2900
AUG 21 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

BURKHARD SCHLÜTERMANN

Examiner: JAMES M. SPEAR

APPLICATION NO: 09/367,361

FILED: AUGUST 11, 1999

FOR: OXACARBAZEPINE FILM-COATED TABLETS

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180.00 for payment of the fee required by 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge the above-mentioned \$180.00 fee and any additional fees which may be required to Deposit Account No. 19-0134 in the name of Novartis Corporation.

08/22/2002 NH08AMH1 00000151 190134 09367361

01 FC:126 180.00 CH

Respectfully submitted,

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6950

Date: August 20, 2002

John D. Thallemer
Attorney for Applicant
Reg. No. 34,940